BPC-157 and TB-500, anti-catabolic complement CagriSema causes the strongest weight reduction of all incretin regimens, the risk of sarcopenia is proportionally the highest
All statements about relative bioavailability are extrapolations from animal pharmacology and general peptide pharmacokinetic principles
Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain
Current research suggests these peptides work synergistically, with BPC-157 primarily driving angiogenesis and cytoprotection while TB-500 focuses on actin-mediated cellular migration and structural remodeling
Mechanism of action in the mouth (oral cavity) Wound healing: Stimulates fibroblast activity, collagen synthesis, and keratinocyte migration, accelerating soft tissue repair (important for periodontal disease, oral ulcers, or mucosal trauma) 2 Anti-inflammatory modulation Reduces neutrophil and macrophage overactivation, limiting collateral damage to gum tissue 3 : Bone and ligament support: Early studies suggest BPC-157 promotes tendon-to-bone healing and osteogenesis, potentially relevant for periodontitis-related bone loss or implant integration
